Table 2. Lower risk features are associated with a diffuse pattern of expression of PTEN in patients with stage 3 neuroblastoma.
No.of patients (% of 53) | # of tumors with PTEN pattern(%, across*) | P-value, Chi-square test | ||
---|---|---|---|---|
Diffuse | Focal or negative | |||
Total | 53 (100%) | 28 (53%) | 25 (47%) | |
MYCN | ||||
Non-amplified | 36 (68%) | 25 (69%) | 11 (31%) | < 0.001 |
Amplified | 17 (32%) | 3 (18%) | 14 (82%) | |
Shimada Classification | ||||
Favorable | 23 (43%) | 19 (83%) | 4 (17%) | < 0.001 |
Unfavorable | 30 (57%) | 9 (30%) | 21 (70%) | |
Age | ||||
≤12 months | 14 (26%) | 9 (64%) | 5 (36%) | 0.28 |
≥12 months | 39 (74%) | 19 (49%) | 20 (51%) | |
≤18 months | 22 (42%) | 14 (64%) | 8 (36%) | 0.25 |
≥18 months | 31 (58%) | 14 (45%) | 17 (55%) | |
MYCN and Shimada classification | ||||
Non-amp/favorable (intermediate risk) | 23 (43%) | 19 (83%) | 4 (17%) | < 0.001 |
Non-amp/unfavorable (all but one are ≥ 12 month old) | 13 (25%) | 6 (46%) | 7 (54%) | |
Amp/favorable | 0 | |||
Amp/unfavorable (high risk) | 17 (32%) | 3 (18%) | 14 (82%) |
*Percentages in the “No. of patients” column refers to percentage out of total 53 patients. Percentages in the PTEN expression columns refers to the percent of patients with that pattern of PTEN staining in that specific risk category (i.e., across the lines).